-
Story
Test story page for non english content -
Story
Test - Story - ContentSync - Translated content pulled from Repository -
Story
test story content
-
Story
Why advocating for your MS is so important -
Press ReleaseNovartis ranks first in 2024 Access to Medicine Index
-
Story
Negative impact of the IRA on patient access to innovative treatments -
Story
A partnership against epilepsy -
Story
Beacon of Hope lights the way for a more equitable future -
Press ReleaseSandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio
-
Press ReleaseSandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
-
Press ReleaseNovartis publie l’invitation à l’AGE et la brochure d’information aux actionnaires. Sandoz publie le prospectus de cotation avant le vote sur la proposition de scission
-
Press ReleaseNovartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote